Shares of Danvers, MA-based Abiomed Inc. (ABMD) surged as much as 27.13% or $10.48 in after hours trading following the release of impressive third-quarter fiscal 2015 financial numbers as well as the ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for ...

Impella RP with SmartAssist is an innovative advancement of Impella RP, which was granted a PMA by the FDA in 2017 and has treated thousands of patients globally with right heart failure or ...

Shares of ABIOMED climbed roughly 0.7% in the trading session following the announcement of the favorable trial results. The Recover Right clinical study commenced after receiving the Investigational ...

ABIOMED Inc.’s ABMD Impella RP recently attained the FDA’s Emergency Use Authorization (EUA) for treating COVID-19-related right heart failure or decompensation, including pulmonary embolism (PE).

Abiomed has issued an urgent medical device correction for its Impella RP and Impella RP Flex series of heart pumps. In a letter sent to customers on January 27, Abiomed said the voluntary device ...

The Impella RP Flex device is placed in the right side of the heart for up to two weeks to help get blood pumping through the organ and out to the lungs at a normal pace for people with right-sided ...

The US Food and Drug Administration has confirmed that patients treated with Abiomed’s Impella RP system had a lower survival rate in a postapproval study than did those treated in preapproval ...

Once implanted into the right side of the heart, the Impella RP system pumps blood from the body’s largest vein, the vena cava, through the heart and into the pulmonary artery. (iStock / Getty Images ...

WASHINGTON -- Abiomed Inc., a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of ...

Abiomed, Inc. ABMD recently received FDA pre-market approval (PMA) for its newest right heart pump — the Impella RP with SmartAssist. The FDA has deemed the new pump as safe and effective when it ...

In March 2017, Abiomed (ABMD) submitted premarket approval (or PMA) to the FDA for its Impella RP device far ahead of schedule. The company expects to secure approval for the device by October 2017 ...